Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Cited by 28 Publications

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472.CAN-16-3424

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )
Cell Death Dis, 2012, 3:e299

PubMed: 22513873 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266 ( click the link to review the publication )

Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930 ( click the link to review the publication )

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55982

PubMed: 23418490 ( click the link to review the publication )
Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/ ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

9 Customer Reviews

In vivo antitumor efﬁcacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.
ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

Cell Death Dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.
HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.
MEF cells were treated for 24 hours with the Bcl-2 antagonists Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.
Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot.

Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnLOJVKSzVyPUCuNFAxODNzNzFOwG0>	NIT0dW1USU6JRWK=
SK-MEL-30	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzoNlM5UUN3ME2wMlAxODN3NTFOwG0>	NXvkZXNZW0GQR1XS
NALM-6	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzSPG8yUUN3ME2wMlAxODN3NjFOwG0>	M3eyeXNCVkeHUh?=
KYSE-450	NH;ERnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVP2eZI1UUN3ME2wMlAxODR4OTFOwG0>	MmHaV2FPT0WU
BHY	M3[zUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jDS2lEPTB;MD6wNFA3ODFizszN	MlvuV2FPT0WU
GR-ST	NGXYN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMECwOlQ5KM7:TR?=	NH70d\|NUSU6JRWK=
786-0	MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmS3TWM2OD1yLkCwNFc4PiEQvF2=	NFrycGlUSU6JRWK=
C-33-A	NGHENGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fZOGlEPTB;MD6wNFA5PDhizszN	NF;MT3VUSU6JRWK=
BHT-101	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTuSJhKSzVyPUCuNFAyODZizszN	Moj4V2FPT0WU
EB2	NFHoe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXXTWM2OD1yLkCwNVE5KM7:TR?=	NE\OOpdUSU6JRWK=
G-361	NFXDZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLLTWM2OD1yLkCwNVI1KM7:TR?=	M1fPeHNCVkeHUh?=
KE-37	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMECxNlgh\|ryP	NX;wbnVMW0GQR1XS
MHH-PREB-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYi2WHdyUUN3ME2wMlAxOTRizszN	M{Pk[nNCVkeHUh?=
MCF7	NWPqNmsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rNWmlEPTB;MD6wNFE2QSEQvF2=	M1PHeXNCVkeHUh?=
LOUCY	NEDGdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPoS45KSzVyPUCuNFAyPzVizszN	NE[wOXVUSU6JRWK=
EW-7	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHrfHJkUUN3ME2wMlAxOTd3IN88US=>	M2nvNXNCVkeHUh?=
KYSE-510	M3XnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlv3TWM2OD1yLkCwNlM{KM7:TR?=	M1HLenNCVkeHUh?=
SK-MEL-3	NY\mbodjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\uc2lEPTB;MD6wNFI3PCEQvF2=	M1S1bXNCVkeHUh?=
HAL-01	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mle2TWM2OD1yLkCwNlk4KM7:TR?=	NEnoNJpUSU6JRWK=
HCC2998	MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HBNWlEPTB;MD6wNFM{PSEQvF2=	M4nkcXNCVkeHUh?=
A375	MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NESwSGZKSzVyPUCuNFA{PSEQvF2=	NX7WVWNQW0GQR1XS
MZ7-mel	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17uW2lEPTB;MD6wNFM6QSEQvF2=	M3LJOHNCVkeHUh?=
SH-4	Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXj1U5YzUUN3ME2wMlAxPDF5IN88US=>	NIHZdHpUSU6JRWK=
HT-144	MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLYOm1jUUN3ME2wMlAxPDNizszN	M1;hV3NCVkeHUh?=
KYSE-140	M4\rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPhN\|VKSzVyPUCuNFA1OzVizszN	NX3od5ppW0GQR1XS
PSN1	Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\xPXhKSzVyPUCuNFA1PjdizszN	NX\zUlhpW0GQR1XS
COLO-679	NIf2c\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWKxXlFGUUN3ME2wMlAxPDl6IN88US=>	MYDTRW5ITVJ?
SW620	M3zsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXMfoRYUUN3ME2wMlAxPTFzIN88US=>	Mn3SV2FPT0WU
HGC-27	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInMNGNKSzVyPUCuNFA2OjRizszN	MmjoV2FPT0WU
IGROV-1	NVnlbZhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMEC2JO69VQ>?	NFfpUWhUSU6JRWK=
IGR-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwMEC2NFEh\|ryP	MW\TRW5ITVJ?
EW-1	NH7xT\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPQ[\|FqUUN3ME2wMlAxPjVzIN88US=>	Ml3YV2FPT0WU
769-P	NELlfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfMZ2hKSzVyPUCuNFA3PzhizszN	MYPTRW5ITVJ?
HN	MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfpTWM2OD1yLkCwOlc6KM7:TR?=	NUfqN\|RkW0GQR1XS
SIG-M5	MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmC4TWM2OD1yLkCwO\|Eh\|ryP	MVPTRW5ITVJ?
IST-MEL1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rCWGlEPTB;MD6wNFgyQCEQvF2=	M4fSOXNCVkeHUh?=
ST486	NEf1TpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjlTWM2OD1yLkCwPFI2KM7:TR?=	M3jye3NCVkeHUh?=
ES7	MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nESmlEPTB;MD6wNFg1PiEQvF2=	MWrTRW5ITVJ?
GAK	NI\IUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXPc2lMUUN3ME2wMlAxQDR6IN88US=>	M1vheHNCVkeHUh?=
BB30-HNC	NH;5[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorOTWM2OD1yLkCwPFU5KM7:TR?=	MYrTRW5ITVJ?
IPC-298	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;BbZlOUUN3ME2wMlAxQTJ5IN88US=>	NYTXXIx5W0GQR1XS
NKM-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjzTGJ{UUN3ME2wMlAxQTd{IN88US=>	M37UOXNCVkeHUh?=
RKO	NGf0[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NED5ZXRKSzVyPUCuNFExPDRizszN	NYfOZXdKW0GQR1XS
ACN	M{H2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnkbpJKSzVyPUCuNFEyOzFizszN	M4rs[nNCVkeHUh?=
SW1417	M3nLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrE[FNKSzVyPUCuNFEzOjVizszN	M2[5eHNCVkeHUh?=
SR	NGfnRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHuwOmdKSzVyPUCuNFEzOzVizszN	MnjVV2FPT0WU
SNG-M	M3vFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\CUmdqUUN3ME2wMlAyOzF5IN88US=>	M4rPcnNCVkeHUh?=
CAL-12T	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\Ue2lEPTB;MD6wNVM1PiEQvF2=	MlTqV2FPT0WU
HSC-3	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMEGzOVUh\|ryP	NYTMWpRHW0GQR1XS
DOHH-2	NH;KTWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmroTWM2OD1yLkCxOFEzKM7:TR?=	NIHHfnpUSU6JRWK=
NB69	NEO2XHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHwd3U1UUN3ME2wMlAyPTZ3IN88US=>	M{jYT3NCVkeHUh?=
LC-2-ad	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4OyW2lEPTB;MD6wNVU5OSEQvF2=	NInz[\|VUSU6JRWK=
RVH-421	NHjiXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjl[5d2UUN3ME2wMlAyPjd2IN88US=>	MXXTRW5ITVJ?
TGW	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmOzTWM2OD1yLkCxO\|M6KM7:TR?=	M2[wbXNCVkeHUh?=
HCC1569	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHPTWM2OD1yLkCxO\|k4KM7:TR?=	NGe4cHRUSU6JRWK=
CAL-85-1	NH3wfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVn6N4JOUUN3ME2wMlAyQDN{IN88US=>	MWjTRW5ITVJ?
RPMI-8402	MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzHTWM2OD1yLkCxPFU5KM7:TR?=	MWLTRW5ITVJ?
THP-1	NFXHW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DyZmlEPTB;MD6wNVk6QCEQvF2=	NGqzZ2VUSU6JRWK=
ONS-76	MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PpeWlEPTB;MD6wNlA{PiEQvF2=	MUXTRW5ITVJ?
A2780	M4XPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TVU2lEPTB;MD6wNlA4QSEQvF2=	MWDTRW5ITVJ?
RPMI-2650	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwMEKyPVYh\|ryP	M1:5NHNCVkeHUh?=
MEL-HO	NIDMfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml32TWM2OD1yLkCyN\|Q5KM7:TR?=	NHfabHZUSU6JRWK=
MC-CAR	M2jPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nUWGlEPTB;MD6wNlM2PiEQvF2=	NWT2Rmc1W0GQR1XS
HSC-2	NGrJWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwMEK0OlYh\|ryP	MVnTRW5ITVJ?
MEL-JUSO	NYPoe4U2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXf6VVE6UUN3ME2wMlAzPDd\|IN88US=>	NUH5bVJjW0GQR1XS
CAL-62	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHBSnpRUUN3ME2wMlAzPjB{IN88US=>	MYjTRW5ITVJ?
DMS-273	NX\D[YxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnyZoZKSzVyPUCuNFI5PDdizszN	M2LMRnNCVkeHUh?=
S-117	M3G2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\lRmlEPTB;MD6wNlkxPiEQvF2=	NG\kSWdUSU6JRWK=
SUP-T1	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnNe4dKSzVyPUCuNFI6PDlizszN	NULuZZI4W0GQR1XS
MZ2-MEL	M4\qfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnWVHg{UUN3ME2wMlAzQTV7IN88US=>	MlP5V2FPT0WU
KYSE-270	M4jYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzlTWM2OD1yLkCyPVc3KM7:TR?=	Ml3GV2FPT0WU
CMK	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnYTWM2OD1yLkCzNFI{KM7:TR?=	MWnTRW5ITVJ?
8505C	NX\NclJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\jc2lEPTB;MD6wN\|A1KM7:TR?=	MV\TRW5ITVJ?
NUGC-3	NXXUTmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwMEOwOFgh\|ryP	MVTTRW5ITVJ?
A101D	M4DwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVixfoRKUUN3ME2wMlA{ODV3IN88US=>	MmniV2FPT0WU
G-401	NIHiNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nWNWlEPTB;MD6wN\|A6OyEQvF2=	M4Pp[nNCVkeHUh?=
OVCAR-8	NFHxbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMEOxNFch\|ryP	NHjpcVdUSU6JRWK=
IMR-5	NHyxRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jtTGlEPTB;MD6wN\|I1PCEQvF2=	MoG4V2FPT0WU
DoTc2-4510	MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlixTWM2OD1yLkCzN\|k{KM7:TR?=	NXHTV\|VUW0GQR1XS
HOS	NEXUS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnI[YREUUN3ME2wMlA{PDd\|IN88US=>	MVrTRW5ITVJ?
HEC-1	M37WbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jJR2lEPTB;MD6wN\|Y5KM7:TR?=	MU\TRW5ITVJ?
SW756	M17XcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEO4NlEh\|ryP	NF[xPYRUSU6JRWK=
NCI-H64	NE\sT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\WTWM2OD1yLkCzPFQzKM7:TR?=	NGXCdXpUSU6JRWK=
EW-16	M4T5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NECwbmtKSzVyPUCuNFM6ODlizszN	NInN[WhUSU6JRWK=
CAL-51	NEGzRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWCyNZhwUUN3ME2wMlA1ODB3IN88US=>	MU\TRW5ITVJ?
KYSE-150	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37zV2lEPTB;MD6wOFAyOSEQvF2=	MUDTRW5ITVJ?
SW1710	M3rObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMESwNVgh\|ryP	NGDHSVFUSU6JRWK=
HuP-T4	MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTPOoVKSzVyPUCuNFQyOThizszN	NFr1XllUSU6JRWK=
LB373-MEL-D	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7zfGRKSzVyPUCuNFQzOzJizszN	NYHReWxUW0GQR1XS
EW-13	M{fMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfTcYVZUUN3ME2wMlA1PDB4IN88US=>	Ml7uV2FPT0WU
HT-29	M3\TSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DBdGlEPTB;MD6wOFQ6KM7:TR?=	NFPoU5BUSU6JRWK=
SCC-25	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXr6WolpUUN3ME2wMlA1PDl2IN88US=>	MoXDV2FPT0WU
REH	MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMES2N\|Uh\|ryP	M364Z3NCVkeHUh?=
L-363	NULQUnRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV:3V\|NoUUN3ME2wMlA1Pjd7IN88US=>	NE\a[oJUSU6JRWK=
NCI-H1770	M2XFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMES2PVch\|ryP	MWnTRW5ITVJ?
CHL-1	M1jDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTTTWM2OD1yLkC0PFU4KM7:TR?=	MXvTRW5ITVJ?
ES1	NWL4fnMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwMES4PFUh\|ryP	NFrxW2FUSU6JRWK=
SCC-15	NXfQW\|RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4e3U2lEPTB;MD6wOFkxOiEQvF2=	NUW4RmhVW0GQR1XS
MRK-nu-1	MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwMES5N\|Yh\|ryP	NEDmcWhUSU6JRWK=
PF-382	M4S0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvFZ\|NKSzVyPUCuNFQ6OzlizszN	NWHjd\|JSW0GQR1XS
COLO-680N	NVmzd2J2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1y5ZmlEPTB;MD6wOVA1PyEQvF2=	NY\aTIpIW0GQR1XS
LK-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nSR2lEPTB;MD6wOVA3OyEQvF2=	MnTYV2FPT0WU
NCI-H2342	M3TZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjiZpNKSzVyPUCuNFUyOTdizszN	M1XMT3NCVkeHUh?=
HMV-II	NVLBWnFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnrVI9EUUN3ME2wMlA2OjN7IN88US=>	NVnlXGl4W0GQR1XS
PC-14	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnm5TWM2OD1yLkC1NlUzKM7:TR?=	M2rsPHNCVkeHUh?=
COLO-320-HSR	M4n3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljyTWM2OD1yLkC1Nlg6KM7:TR?=	MUTTRW5ITVJ?
697	MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLRdGRKSzVyPUCuNFU{OjNizszN	NULYU4hyW0GQR1XS
NEC8	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMEW1PUDPxE1?	M2rmN3NCVkeHUh?=
LCLC-97TM1	NFfPeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHpbXZMUUN3ME2wMlA2PTl2IN88US=>	MmjsV2FPT0WU
Daoy	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;oc4J6UUN3ME2wMlA2PjF4IN88US=>	MkXXV2FPT0WU
ETK-1	MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3LTWM2OD1yLkC1OlczKM7:TR?=	M2fDWXNCVkeHUh?=
A388	M1[0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnz6TWM2OD1yLkC1Olk2KM7:TR?=	M3m3XHNCVkeHUh?=
COLO-205	NXvpPJNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMEW3NVYh\|ryP	MnPHV2FPT0WU
SK-PN-DW	NWm2WJlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\PTWM2OD1yLkC1O\|I6KM7:TR?=	M1;zcnNCVkeHUh?=
SF268	NIP3[\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMEW3OVYh\|ryP	MmCxV2FPT0WU
OCI-AML2	NHzLZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XTSmlEPTB;MD6wOVc4PyEQvF2=	NGi1XHRUSU6JRWK=
GAMG	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMEW4JO69VQ>?	M{DFc3NCVkeHUh?=
BCPAP	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfKXJJKSzVyPUCuNFU5QTJizszN	MX7TRW5ITVJ?
BC-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnviTWM2OD1yLkC2NFIzKM7:TR?=	MkK3V2FPT0WU
IA-LM	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PzRWlEPTB;MD6wOlA2OyEQvF2=	NIXEXVNUSU6JRWK=
NCI-H1299	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHWT4ZHUUN3ME2wMlA3OTNizszN	MUXTRW5ITVJ?
COR-L23	NHLHSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHjRoNZUUN3ME2wMlA3OTN2IN88US=>	MYDTRW5ITVJ?
KYSE-180	NHTDNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfqTWM2OD1yLkC2NVQzKM7:TR?=	NXHpbphQW0GQR1XS
LOXIMVI	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwME[xPFgh\|ryP	MWLTRW5ITVJ?
BL-41	NU\rU2ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPCc49KSzVyPUCuNFYzOTlizszN	NFTTSlVUSU6JRWK=
BL-70	NW\SOJltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwME[zNFIh\|ryP	MoXhV2FPT0WU
NOS-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPpcFNKSzVyPUCuNFY1OTFizszN	NF2xe2JUSU6JRWK=
NB13	NV;nSphbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{OyfGlEPTB;MD6wOlQzOSEQvF2=	M2f2bnNCVkeHUh?=
CAL-27	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;aTWM2OD1yLkC2OFY1KM7:TR?=	MnjuV2FPT0WU
CA46	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwME[1N\|ch\|ryP	NFT3U3pUSU6JRWK=
SW962	MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nMXGlEPTB;MD6wOlU3QSEQvF2=	M4fpTHNCVkeHUh?=
NCI-H226	NWn6NoE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwME[2N\|Ih\|ryP	MY\TRW5ITVJ?
KYSE-70	NVjmZ4V1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvpRo1KSzVyPUCuNFY6PDVizszN	M{TlZnNCVkeHUh?=
Daudi	M2TvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\qTWM2OD1yLkC3NFgyKM7:TR?=	MYfTRW5ITVJ?
SW626	M{S2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHNVIF3UUN3ME2wMlA4OjB2IN88US=>	MXXTRW5ITVJ?
ESS-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMEeyOFYh\|ryP	Mlj2V2FPT0WU
YT	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7QeJZKSzVyPUCuNFc{PDVizszN	NITpPFBUSU6JRWK=
P12-ICHIKAWA	NVfEcndMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwMEezOFkh\|ryP	MoHmV2FPT0WU
BxPC-3	NXLvRnBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHBTWM2OD1yLkC3OFU5KM7:TR?=	M3;WVXNCVkeHUh?=
CTV-1	MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwMEe1NVch\|ryP	M3:wWXNCVkeHUh?=
MLMA	NELUWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mne0TWM2OD1yLkC3OVM1KM7:TR?=	NXvU[nZ7W0GQR1XS
WSU-NHL	NFSybopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMEe1OVQh\|ryP	NInCdW9USU6JRWK=
CTB-1	NUj5OIVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jTXmlEPTB;MD6wO\|U5QCEQvF2=	NIrOUFdUSU6JRWK=
MMAC-SF	NHixd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\kTWM2OD1yLkC3OlY5KM7:TR?=	NWL6U2tJW0GQR1XS
8-MG-BA	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\EUlZKSzVyPUCuNFc5ODFizszN	MW\TRW5ITVJ?
NCI-H358	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlOzTWM2OD1yLkC3PFc6KM7:TR?=	MYnTRW5ITVJ?
BFTC-905	M3;UUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTuU\|h2UUN3ME2wMlA4QTB7IN88US=>	NXjJeJRqW0GQR1XS
NCI-H727	NXHpb204T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvvSFZKSzVyPUCuNFgxPTNizszN	NXq0VJJ3W0GQR1XS
CHP-212	NV;NbHg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwMEiwPVUh\|ryP	MVjTRW5ITVJ?
HOP-62	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PubmlEPTB;MD6wPFI1PSEQvF2=	NYLpXoRwW0GQR1XS
CESS	NE[xT\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMEiyOlkh\|ryP	MUfTRW5ITVJ?
HuCCT1	MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPCTWM2OD1yLkC4N\|M{KM7:TR?=	NGL6XFNUSU6JRWK=
DEL	M3[1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMEizOFch\|ryP	NVjmOJVxW0GQR1XS
5637	NHTBVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\0VolKSzVyPUCuNFg{PjdizszN	MVnTRW5ITVJ?
RS4-11	NVv4bYd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHDTWM2OD1yLkC4OFk4KM7:TR?=	NUHacVk2W0GQR1XS
KURAMOCHI	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMEi1NFkh\|ryP	NFHUd4FUSU6JRWK=
A427	NEPPXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMEi1NVIh\|ryP	NEjjRY9USU6JRWK=
A3-KAW	M3\1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;PTWM2OD1yLkC4OVY3KM7:TR?=	NUWwWY1pW0GQR1XS
LS-123	M13nOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HOdWlEPTB;MD6wPFcyQSEQvF2=	NEK3WZhUSU6JRWK=
LoVo	M1\JZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnBdXk2UUN3ME2wMlA5PzJizszN	NFLS[FhUSU6JRWK=
PA-1	NH;wNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwMEi3Olkh\|ryP	NV\RbWNWW0GQR1XS
CP50-MEL-B	MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fobWlEPTB;MD6wPFc6OyEQvF2=	Mof0V2FPT0WU
A431	NYXlNIkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMEi4NFEh\|ryP	NGmxWXpUSU6JRWK=
HCT-116	MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHFTWM2OD1yLkC4PFAzKM7:TR?=	MX7TRW5ITVJ?
A4-Fuk	NHjGPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkC3TWM2OD1yLkC4PVQ4KM7:TR?=	NHfpW2hUSU6JRWK=
RPMI-6666	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETjcIRKSzVyPUCuNFg6PjdizszN	NHP6doZUSU6JRWK=
Calu-6	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMEmwNlkh\|ryP	Mln3V2FPT0WU
KMOE-2	NYTlXGQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlH1TWM2OD1yLkC5NFM6KM7:TR?=	M{K0TXNCVkeHUh?=
A704	NHTMZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1npTGlEPTB;MD6wPVE2KM7:TR?=	NHH3eWhUSU6JRWK=
HO-1-N-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlG5TWM2OD1yLkC5NlQ6KM7:TR?=	Moq5V2FPT0WU
NCI-H2122	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjPcGZKSzVyPUCuNFk{PzhizszN	MWnTRW5ITVJ?
U-698-M	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXLVIpKSzVyPUCuNFk1ODlizszN	NVPsbHM6W0GQR1XS
IST-SL2	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHnbFg5UUN3ME2wMlA6PDZ6IN88US=>	M4q5bXNCVkeHUh?=
TE-10	NFv0RodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\qWZVKSzVyPUCuNFk2QDRizszN	M37vbHNCVkeHUh?=
PANC-03-27	NFjhO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;iXoNnUUN3ME2wMlA6PjdzIN88US=>	MkTVV2FPT0WU
KYSE-410	M3LyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3u3V2lEPTB;MD6wPVc6PyEQvF2=	MY\TRW5ITVJ?
TE-8	NX3DeWh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LE[GlEPTB;MD6wPVg5PSEQvF2=	NWLZXYNpW0GQR1XS
MN-60	NHqz[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX2yc4N1UUN3ME2wMlA6QDl5IN88US=>	NUDIem9RW0GQR1XS
NCI-H460	NHr3b\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXFTWM2OD1yLkGwNFkh\|ryP	NELwflFUSU6JRWK=
LB771-HNC	MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPhemdHUUN3ME2wMlExOjV3IN88US=>	MlXGV2FPT0WU
ES4	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjrTWM2OD1yLkGwNlY1KM7:TR?=	NGDiZXFUSU6JRWK=
HUTU-80	NGXSNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\WWmlEPTB;MD6xNFM3PSEQvF2=	MUTTRW5ITVJ?
647-V	M4jsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLLXXhKSzVyPUCuNVA1ODhizszN	NX7p[Id6W0GQR1XS
HTC-C3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnWTWM2OD1yLkGwOFMzKM7:TR?=	MYTTRW5ITVJ?
NTERA-S-cl-D1	NEDTe5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMUC0OFgh\|ryP	MYLTRW5ITVJ?
A2058	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHO2c3VKSzVyPUCuNVA3PTVizszN	NGnES3FUSU6JRWK=
MZ1-PC	M4rXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjGOIJKSzVyPUCuNVA5OyEQvF2=	NHG3RWNUSU6JRWK=
J82	MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTzPXZKSzVyPUCuNVA5QDRizszN	M2n6N3NCVkeHUh?=
ARH-77	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwMUGg{txO	NY\ZdVFzW0GQR1XS
Ca9-22	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkGyTWM2OD1yLkGxNVI5KM7:TR?=	MYPTRW5ITVJ?
NCI-H1648	M1q1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMUGyPFYh\|ryP	NIfzflRUSU6JRWK=
MC116	NYq2O2dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMUGzN\|ch\|ryP	NUPxZoFSW0GQR1XS
EoL-1-cell	NHW2OoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjCSZdnUUN3ME2wMlEyPDZ5IN88US=>	NFfWdG9USU6JRWK=
PANC-10-05	NIjHb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPPTWM2OD1yLkGxOFkyKM7:TR?=	NXnZdYZZW0GQR1XS
SF539	M2DwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMUG2NVYh\|ryP	M1LKeXNCVkeHUh?=
ES8	NIHJV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\4PFN{UUN3ME2wMlEyPjN\|IN88US=>	NEDjT41USU6JRWK=
NCI-H810	NWXWcW9ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXIPI9KSzVyPUCuNVE3PjRizszN	M1\ycnNCVkeHUh?=
J-RT3-T3-5	M2Szfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jRUGlEPTB;MD6xNVc2KM7:TR?=	MXnTRW5ITVJ?
NY	NHewTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPm[IdZUUN3ME2wMlEyQDF5IN88US=>	MnHGV2FPT0WU
NCI-SNU-1	MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LMOWlEPTB;MD6xNlE1QCEQvF2=	Mk[2V2FPT0WU
EFM-19	NFXwUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGL1S\|ZKSzVyPUCuNVI{PzRizszN	MULTRW5ITVJ?
HCC1806	M4HVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELNbHpKSzVyPUCuNVI{QDNizszN	MU\TRW5ITVJ?
HCE-T	MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMUK1N\|Eh\|ryP	NX3xT4VGW0GQR1XS
HT-1376	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX:yeJl6UUN3ME2wMlEzPjZ6IN88US=>	Mmr0V2FPT0WU
BE-13	NInxOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PW[GlEPTB;MD6xNlg3PiEQvF2=	M1\VbHNCVkeHUh?=
NCI-H520	MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIm2THBKSzVyPUCuNVI5PjdizszN	MV\TRW5ITVJ?
SK-MES-1	NVLCPVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTBwMUK5NVMh\|ryP	NVTUU2xQW0GQR1XS
SNU-423	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwMUK5NVQh\|ryP	Ml2zV2FPT0WU
Ramos-2G6-4C10	NHy3NZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwMUK5NVYh\|ryP	MW\TRW5ITVJ?
EW-18	NEDnZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDkTWM2OD1yLkGzNFI3KM7:TR?=	NUfCNHpFW0GQR1XS
NCI-H2087	M33tT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrkcpRKSzVyPUCuNVMxOjdizszN	MUnTRW5ITVJ?
COLO-792	NWT2[IFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;iSWlEPTB;MD6xN\|E3PSEQvF2=	NXO3e4h7W0GQR1XS
QIMR-WIL	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnYTWM2OD1yLkGzNlI{KM7:TR?=	M4HXe3NCVkeHUh?=
ACHN	M1\3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTlTWM2OD1yLkGzNlQ4KM7:TR?=	Mn7TV2FPT0WU
RPMI-8866	M2DJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwMUOyOlEh\|ryP	MorvV2FPT0WU
SK-LU-1	NHXnPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2i0PWlEPTB;MD6xN\|Q1QSEQvF2=	NH7ZdolUSU6JRWK=
SK-UT-1	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVG0bYhXUUN3ME2wMlE{PjJ6IN88US=>	Mlv1V2FPT0WU
MFE-296	NW\lNlNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWL0dJRrUUN3ME2wMlE{QDZ2IN88US=>	M1fOcXNCVkeHUh?=
RD	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfLVJZKSzVyPUCuNVM6QTdizszN	MmDvV2FPT0WU
LS-411N	M{\xW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoftTWM2OD1yLkG0Nlk2KM7:TR?=	NUXlWJltW0GQR1XS
NCI-H747	NH64eldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGKwNGtKSzVyPUCuNVQ{KM7:TR?=	NV3jfZpnW0GQR1XS
ES6	NXXvOWdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMUSzOkDPxE1?	MVLTRW5ITVJ?
TE-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3y4[GlEPTB;MD6xOFQxPyEQvF2=	M2\WcHNCVkeHUh?=
SJSA-1	NUHhfJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3kSotKSzVyPUCuNVQ4ODdizszN	M{P1UHNCVkeHUh?=
NCI-H1355	M{DTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMUWyPVMh\|ryP	NUK4cY0{W0GQR1XS
HEL	NYP2[ng6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjGS45JUUN3ME2wMlE2PDR5IN88US=>	M3vuOXNCVkeHUh?=
639-V	M4DDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjrb\|NKSzVyPUCuNVU2QTZizszN	M1rFPXNCVkeHUh?=
AN3-CA	M1\GPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjxdIxQUUN3ME2wMlE2PjN7IN88US=>	NWC0Tpk1W0GQR1XS
SK-MEL-2	NWHJRZhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofCTWM2OD1yLkG1OlY5KM7:TR?=	NHHwbVFUSU6JRWK=
SW872	NGDlR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PoUGlEPTB;MD6xOlA1OiEQvF2=	M{XGUXNCVkeHUh?=
DU-4475	M3jwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwMU[xOlIh\|ryP	NHj3d2FUSU6JRWK=
YKG-1	NUDkNYU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnPTWM2OD1yLkG2Nlc{KM7:TR?=	NV\CN41lW0GQR1XS
GT3TKB	NWrDUXplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXy0V5l5UUN3ME2wMlE3Ojh\|IN88US=>	M1;5XHNCVkeHUh?=
GB-1	M4rQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMU[0NlQh\|ryP	Mn71V2FPT0WU
KARPAS-422	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMU[1O\|Qh\|ryP	NIjWbZVUSU6JRWK=
ATN-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfGW4lKSzVyPUCuNVY3PTZizszN	MmXWV2FPT0WU
HLE	MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHLTWM2OD1yLkG2PFc4KM7:TR?=	MmfqV2FPT0WU
D-542MG	NFfEUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjUTWM2OD1yLkG2PVg3KM7:TR?=	NFOzXZJUSU6JRWK=
EB-3	NW\FV5RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;SW5VKSzVyPUCuNVc{OSEQvF2=	MmT3V2FPT0WU
HCC1143	MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXCNFBKSzVyPUCuNVc{QTZizszN	Ml;lV2FPT0WU
DJM-1	NYfaWZBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvWV\|dKSzVyPUCuNVc1PTFizszN	MWrTRW5ITVJ?
BT-474	MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PUZWlEPTB;MD6xO\|Q5QSEQvF2=	NHftdplUSU6JRWK=
BB65-RCC	NVPzdXNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{m3PGlEPTB;MD6xO\|U1PSEQvF2=	NVn4fJJuW0GQR1XS
NCI-H292	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVG1dZM5UUN3ME2wMlE4PjBzIN88US=>	M3;BZXNCVkeHUh?=
MKN28	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMUe2OVMh\|ryP	NUX0VWtKW0GQR1XS
TK10	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;4b2lEPTB;MD6xO\|cxOiEQvF2=	MUHTRW5ITVJ?
TYK-nu	MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfxTWM2OD1yLkG3PVQ6KM7:TR?=	M3juR3NCVkeHUh?=
8305C	MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7STWM2OD1yLkG3PVcyKM7:TR?=	MV\TRW5ITVJ?
MV-4-11	NUi4Z2U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f2UmlEPTB;MD6xO\|k4PyEQvF2=	NInNR5dUSU6JRWK=
NCI-H522	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M161[GlEPTB;MD6xPFA6PCEQvF2=	NFPEfIpUSU6JRWK=
Hs-578-T	NYLWcW9xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMUiyPVIh\|ryP	MXPTRW5ITVJ?
LCLC-103H	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfyfnFEUUN3ME2wMlE5PTJ5IN88US=>	NInrepZUSU6JRWK=
MHH-ES-1	M37mVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYG3[ZBOUUN3ME2wMlE5PjJ7IN88US=>	MoDsV2FPT0WU
NCI-H441	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWqzcWM2UUN3ME2wMlE6OTR6IN88US=>	M3z5cXNCVkeHUh?=
AM-38	MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMUmyNlUh\|ryP	MnX6V2FPT0WU
SW1783	NGi4N5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMUmzNFUh\|ryP	NF\ITFVUSU6JRWK=
SK-HEP-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHYTWM2OD1yLkG5OlM4KM7:TR?=	MUnTRW5ITVJ?
OAW-28	NVrEenVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILSVmJKSzVyPUCuNlAyPzhizszN	MVTTRW5ITVJ?
TE-15	M4fOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2S1[GlEPTB;MD6yNFI2OiEQvF2=	NYjmUIVbW0GQR1XS
HCE-4	MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvGcolKSzVyPUCuNlAzQDRizszN	NYm2VHIzW0GQR1XS
JiyoyeP-2003	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XkR2lEPTB;MD6yNFM{PiEQvF2=	MXjTRW5ITVJ?
OVCAR-4	Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2GwcGlEPTB;MD6yNFYzQCEQvF2=	Ml3QV2FPT0WU
SNU-449	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPpUlR4UUN3ME2wMlIxPzl5IN88US=>	MXXTRW5ITVJ?
SBC-5	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPnTWM2OD1yLkKxNlE2KM7:TR?=	Mk\ZV2FPT0WU
T84	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfMNXZKSzVyPUCuNlEzPDhizszN	MVjTRW5ITVJ?
LP-1	M{foNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmGxTWM2OD1yLkKxN\|AzKM7:TR?=	MmrTV2FPT0WU
MG-63	M4r2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLMTWM2OD1yLkKxN\|gzKM7:TR?=	MmO3V2FPT0WU
OAW-42	NEfSfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;vZmlEPTB;MD6yNVQ4QCEQvF2=	MVXTRW5ITVJ?
L-540	NELCZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMkG1PVgh\|ryP	NXT5d2lbW0GQR1XS
RH-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPq[YJKSzVyPUCuNlIzPDJizszN	M1LnNHNCVkeHUh?=
HCT-15	NV\U[21vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlSwTWM2OD1yLkKyOFg1KM7:TR?=	NYm2XnY4W0GQR1XS
OCUB-M	MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnu2TWM2OD1yLkKyOFg5KM7:TR?=	M2XpWHNCVkeHUh?=
GP5d	Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml[5TWM2OD1yLkKyOVI5KM7:TR?=	M3XPb3NCVkeHUh?=
NCI-H2030	MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHjTWM2OD1yLkKyO\|M1KM7:TR?=	Mlz0V2FPT0WU
ML-2	Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXtTWM2OD1yLkKyPFg6KM7:TR?=	NXvzSmdSW0GQR1XS
CAL-39	NIPOelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fBfWlEPTB;MD6yNlk{PiEQvF2=	MVnTRW5ITVJ?
MIA-PaCa-2	M2LwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PMcGlEPTB;MD6yN\|I5PyEQvF2=	MoHiV2FPT0WU
TE-9	M2DqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTBN2hzUUN3ME2wMlI{OzJizszN	MonXV2FPT0WU
LB2518-MEL	M{PXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFntc\|JKSzVyPUCuNlM{PzJizszN	M3zuNXNCVkeHUh?=
DB	M4r2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3iO5VLUUN3ME2wMlI{PDN6IN88US=>	MlrpV2FPT0WU
NCI-H596	NHLjOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPvUVlKSzVyPUCuNlM2PzFizszN	MXjTRW5ITVJ?
SW1990	MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMkO5OFYh\|ryP	NXLifpl4W0GQR1XS
P30-OHK	M37LTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3QSmg6UUN3ME2wMlI1ODVizszN	MUPTRW5ITVJ?
ALL-PO	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnpTWM2OD1yLkK0NVY6KM7:TR?=	M4DQOnNCVkeHUh?=
Saos-2	NYrt[Yk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:wcIFKSzVyPUCuNlQ2PzFizszN	MoTDV2FPT0WU
MFH-ino	NGWzPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjhfYZKSzVyPUCuNlQ3QTJizszN	NWC0RmZtW0GQR1XS
OE33	NGjtVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjaSZNLUUN3ME2wMlI2OTFizszN	M3PnS3NCVkeHUh?=
Calu-3	MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fLT2lEPTB;MD6yOVI6PyEQvF2=	M1LDZ3NCVkeHUh?=
HT	M3n6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDVRZJKSzVyPUCuNlU3OjFizszN	NH7PSIxUSU6JRWK=
LXF-289	NW\pXmxMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMkW5PFQh\|ryP	M3TW[HNCVkeHUh?=
KGN	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnoWmFKSzVyPUCuNlYxQDlizszN	MVTTRW5ITVJ?
NCI-H1417	M2TpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLUUY1KSzVyPUCuNlY2OjRizszN	MYHTRW5ITVJ?
SF126	NIL6TZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUj0T\|ROUUN3ME2wMlI4OzB{IN88US=>	MYTTRW5ITVJ?
SAS	NHrld4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMkezNFgh\|ryP	MoOzV2FPT0WU
22RV1	NVLYTFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3L2R2lEPTB;MD6yO\|M4QCEQvF2=	NITlXoJUSU6JRWK=
GI-1	NWfHRnVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHURY1iUUN3ME2wMlI4PDh5IN88US=>	M{HrOnNCVkeHUh?=
ES3	M1j6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHsd21KSzVyPUCuNlc4PjNizszN	NX3FVodJW0GQR1XS
NB1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWr5VI5GUUN3ME2wMlI4QDd4IN88US=>	MULTRW5ITVJ?
NCI-H650	NXm4U29HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITqNGhKSzVyPUCuNlg{ODJizszN	M2DOb3NCVkeHUh?=
IST-MES1	Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMki1OVQh\|ryP	M4PMdHNCVkeHUh?=
UM-UC-3	NIn4T5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLwTWM2OD1yLkK5NVQh\|ryP	MWnTRW5ITVJ?
CAL-120	M1zWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMkm2N\|Eh\|ryP	NUTxfYlwW0GQR1XS
UACC-62	MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfPfZRKSzVyPUCuN\|AzPDFizszN	NXzFRodSW0GQR1XS
TE-11	M2qySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHoTWM2OD1yLkOwNlQ6KM7:TR?=	MnjnV2FPT0WU
MKN1	M13IXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwM{CzOkDPxE1?	NGTjW3BUSU6JRWK=
KS-1	NX76dpNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrpXXM2UUN3ME2wMlMxPTJ4IN88US=>	MlfiV2FPT0WU
GCIY	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPBXW86UUN3ME2wMlMyODB{IN88US=>	M4DLb3NCVkeHUh?=
OVCAR-5	NVjzPG53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzYbmlKSzVyPUCuN\|EyODZizszN	M4fHbHNCVkeHUh?=
U-266	M4DG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwM{GxOFch\|ryP	NFrVSZFUSU6JRWK=
Calu-1	NVHMZm1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Tte2lEPTB;MD6zNVI5QSEQvF2=	NFPTO\|lUSU6JRWK=
SK-LMS-1	MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwM{G0Nlkh\|ryP	NXzzc5M{W0GQR1XS
COLO-741	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDsTWM2OD1yLkOxOlE1KM7:TR?=	MXXTRW5ITVJ?
RPMI-8226	M362N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwM{G2OFEh\|ryP	NEOy[pZUSU6JRWK=
KM12	NET4e29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjoXpVKSzVyPUCuN\|E5OyEQvF2=	M{LiPXNCVkeHUh?=
NMC-G1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV74dY83UUN3ME2wMlMyQDZizszN	M4HoO3NCVkeHUh?=
SJRH30	MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwM{KwOVIh\|ryP	MlmwV2FPT0WU
COR-L105	NGLvZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2OyVGlEPTB;MD6zNlIyQCEQvF2=	MWDTRW5ITVJ?
IM-9	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnW0TWM2OD1yLkOzNFIyKM7:TR?=	NY\sUFd{W0GQR1XS
TE-12	NVqwWFFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwM{OzNVch\|ryP	MoS3V2FPT0WU
KG-1	NHO4dlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwM{O0N\|Ih\|ryP	MmX1V2FPT0WU
U251	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4T4ZWlEPTB;MD6zN\|Q2PiEQvF2=	MmLOV2FPT0WU
EFO-27	NYr6b5lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3v6WGlEPTB;MD6zN\|k2OSEQvF2=	NYTiXo5JW0GQR1XS
EW-24	NFz3WWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwM{O5PFQh\|ryP	M{nlZnNCVkeHUh?=
SF295	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV61cZRGUUN3ME2wMlM{QTl7IN88US=>	Mlz4V2FPT0WU
MC-IXC	NIrDVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwM{S1JO69VQ>?	MVjTRW5ITVJ?
NCI-H2405	MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vVTWlEPTB;MD6zOFc{OiEQvF2=	Mn\DV2FPT0WU
NCI-H2009	NUfOPG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXlTWM2OD1yLkO0O\|M6KM7:TR?=	NE\vcnpUSU6JRWK=
LB1047-RCC	M2q2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfOTWM2OD1yLkO1PFE2KM7:TR?=	M1ntNnNCVkeHUh?=
KNS-81-FD	M3PGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7qbHFKSzVyPUCuN\|Y3PjdizszN	MnTVV2FPT0WU
HOP-92	M1zaemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXtRmRNUUN3ME2wMlM3QDNizszN	MV7TRW5ITVJ?
L-428	Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFj6[\|NKSzVyPUCuN\|cxOTZizszN	Ml\vV2FPT0WU
C3A	M37ZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moi0TWM2OD1yLkO3N\|c6KM7:TR?=	MVHTRW5ITVJ?
NCI-H1792	NFz0dpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfYTWM2OD1yLkO3OlU2KM7:TR?=	NFjIeWtUSU6JRWK=
HuH-7	NGq0bolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfS[HpKSzVyPUCuN\|c6OSEQvF2=	NGjJUGtUSU6JRWK=
AGS	NFS4PYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVm5U4FjUUN3ME2wMlM5PjN6IN88US=>	MmnuV2FPT0WU
HT-1197	MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrzclZKSzVyPUCuN\|k1PiEQvF2=	NWHFN\|BxW0GQR1XS
CGTH-W-1	M3;XS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;ubmNrUUN3ME2wMlM6QTF\|IN88US=>	MorLV2FPT0WU
KNS-42	MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLCTWM2OD1yLkSwNFQ2KM7:TR?=	M1HIdHNCVkeHUh?=
HuO-3N1	NWXEToVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M163OGlEPTB;MD60NFA2PSEQvF2=	Ml;QV2FPT0WU
VMRC-RCZ	NX;ueYYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLNe3kzUUN3ME2wMlQxOzB\|IN88US=>	MV\TRW5ITVJ?
SW954	MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\PNVVKSzVyPUCuOFA{OzVizszN	MUTTRW5ITVJ?
MES-SA	MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwNEC1NFUh\|ryP	NXPtUYo4W0GQR1XS
Ca-Ski	NISwfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXte\|ZKSzVyPUCuOFA2OjRizszN	MU\TRW5ITVJ?
SW13	MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfCTWM2OD1yLkSwOlI3KM7:TR?=	M3L3SnNCVkeHUh?=
NCI-H1437	MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWK5SYtJUUN3ME2wMlQxQDB3IN88US=>	MkTwV2FPT0WU
U-118-MG	NHjjfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPnTFVKSzVyPUCuOFA6ODRizszN	NVeyd\|BbW0GQR1XS
NCI-H1734	NEPxVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwNEKwNVMh\|ryP	NX\CUZBRW0GQR1XS
HDLM-2	Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXyTWM2OD1yLkSyNFM{KM7:TR?=	Mn\yV2FPT0WU
AU565	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DXb2lEPTB;MD60NlQ3QCEQvF2=	MWfTRW5ITVJ?
FADU	M2jaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\1TGRKSzVyPUCuOFI3PDlizszN	NIXUSWxUSU6JRWK=
OS-RC-2	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjDOmFDUUN3ME2wMlQ{ODh\|IN88US=>	NIfneGhUSU6JRWK=
CAMA-1	NXixeIJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYH0NXlLUUN3ME2wMlQ{PjJ4IN88US=>	NFvoe4tUSU6JRWK=
MONO-MAC-6	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n5N2lEPTB;MD60N\|g1QSEQvF2=	MYDTRW5ITVJ?
LB831-BLC	M4LzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELodoxKSzVyPUCuOFQ{PzFizszN	MkfrV2FPT0WU
SW982	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwNES1Nlgh\|ryP	MYHTRW5ITVJ?
SCC-3	MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3JO5Z3UUN3ME2wMlQ1PTd7IN88US=>	NX30PWNmW0GQR1XS
C32	NYf2PZVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwNEWyNlkh\|ryP	M{nTcXNCVkeHUh?=
BFTC-909	NXS3fW5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrtTWM2OD1yLkS1Nlk6KM7:TR?=	MWrTRW5ITVJ?
MEG-01	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwNEWzO\|Mh\|ryP	M{[xUnNCVkeHUh?=
M14	NXH5U5FvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnnZXRKSzVyPUCuOFU6PzlizszN	MorpV2FPT0WU
MPP-89	M4DGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fYe2lEPTB;MD60OlI2PiEQvF2=	MXjTRW5ITVJ?
HCC1937	M{HPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTqfnhKSzVyPUCuOFY{QDRizszN	NVmydXNqW0GQR1XS
SW837	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vEPGlEPTB;MD60OlczOiEQvF2=	NGDveWRUSU6JRWK=
DU-145	NEXJWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHGXYpKSzVyPUCuOFY4OjlizszN	NUnvSlBFW0GQR1XS
LB996-RCC	NXu0UG1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHNTWM2OD1yLkS3NFU1KM7:TR?=	NFfL[IJUSU6JRWK=
C8166	NUjye3BzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnFSFhCUUN3ME2wMlQ4PCEQvF2=	M{Owb3NCVkeHUh?=
MOLT-4	NGfUcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDrTWM2OD1yLkS3O\|M1KM7:TR?=	MVvTRW5ITVJ?
DMS-53	NXnzVI9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DYXGlEPTB;MD60O\|gxQSEQvF2=	MWjTRW5ITVJ?
TE-5	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\wSGlEPTB;MD60PFMxPSEQvF2=	MmjqV2FPT0WU
KYSE-520	NV73Z3JFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzI[3lKSzVyPUCuOFg{PDNizszN	NYPMRnRrW0GQR1XS
Detroit562	NW\uc3RVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwNEi4OkDPxE1?	MoPoV2FPT0WU
SIMA	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEX3PW1KSzVyPUCuOFk1OTdizszN	NV:0b4lUW0GQR1XS
NCI-H1651	MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zZc2lEPTB;MD60PVY4KM7:TR?=	NVfme\|BtW0GQR1XS
HCC1599	NW\DTJg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjPTWM2OD1yLkS5PVU2KM7:TR?=	NVvVboVzW0GQR1XS
ABC-1	NVvLPINlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfqTWM2OD1yLkWwOFk3KM7:TR?=	MmD5V2FPT0WU
CAL-33	NVmwbY5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnW1TWM2OD1yLkWwPFQ1KM7:TR?=	M1jSW3NCVkeHUh?=
OPM-2	NFTo[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2[1cGlEPTB;MD61NFk{PyEQvF2=	MVfTRW5ITVJ?
RPMI-7951	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;SZVBKSzVyPUCuOVA6PTdizszN	Mne3V2FPT0WU
HT-1080	NHT2NXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{D5UWlEPTB;MD61NVEyQSEQvF2=	NVTNWmN3W0GQR1XS
LC4-1	M{f6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofqTWM2OD1yLkWxOFA{KM7:TR?=	Ml;MV2FPT0WU
OVCAR-3	MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\oTWM2OD1yLkWxOVch\|ryP	MkexV2FPT0WU
CAPAN-1	MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwNUKyPFgh\|ryP	MXjTRW5ITVJ?
SK-OV-3	M3Lacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;pTWM2OD1yLkWyOFM1KM7:TR?=	NXu2bYN{W0GQR1XS
HuP-T3	NV;n[ZQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfMOoRyUUN3ME2wMlUzQDJ5IN88US=>	MXzTRW5ITVJ?
NCI-H838	M3jNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3:3VmlEPTB;MD61Nlg1QSEQvF2=	NUXJUGJ1W0GQR1XS
K5	MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrCNXdvUUN3ME2wMlU{OjBzIN88US=>	NVXoVpBLW0GQR1XS
CAL-72	MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXSRWkyUUN3ME2wMlU{Ozh5IN88US=>	NUDJc5Z{W0GQR1XS
NH-12	NHfYOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1v1WGlEPTB;MD61N\|k2QSEQvF2=	M4HSTHNCVkeHUh?=
SNB75	MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M16xO2lEPTB;MD61OVc{KM7:TR?=	MVnTRW5ITVJ?
BPH-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PMeWlEPTB;MD61OlM1PCEQvF2=	M4G3OHNCVkeHUh?=
NOMO-1	NYHSTJpST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwNU[zO\|Ih\|ryP	NEj4dVRUSU6JRWK=
G-402	NULo[IxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17mSWlEPTB;MD61OlQ6QSEQvF2=	Mnq1V2FPT0WU
NCI-H2052	NEPkXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n0eGlEPTB;MD61Olc1OSEQvF2=	M{\0eXNCVkeHUh?=
RCM-1	M3:5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITyVohKSzVyPUCuOVcyPjZizszN	MVLTRW5ITVJ?
COR-L279	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfsTWM2OD1yLkW3NVg2KM7:TR?=	M3PESHNCVkeHUh?=
A253	MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwNUe1NlUh\|ryP	MkfCV2FPT0WU
SK-MM-2	NIrxN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;ZTWM2OD1yLkW3Olc6KM7:TR?=	NYTzcWN3W0GQR1XS
NCI-H1703	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DQWGlEPTB;MD61PVQzPyEQvF2=	MmLkV2FPT0WU
UACC-257	MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\rTWM2OD1yLkW5OFg4KM7:TR?=	NWrWfHB5W0GQR1XS
KALS-1	NFzsUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvZTWM2OD1yLk[wNFEyKM7:TR?=	MX;TRW5ITVJ?
ES5	M4fyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7BUGltUUN3ME2wMlYxPDhizszN	MoCwV2FPT0WU
MHH-CALL-2	M37pU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwNkC4PFgh\|ryP	MYHTRW5ITVJ?
ChaGo-K-1	NUT6VW86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vwUGlEPTB;MD62NVIzQSEQvF2=	MlrSV2FPT0WU
TGBC1TKB	M4nhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDoTWM2OD1yLk[xPVgh\|ryP	M4H6V3NCVkeHUh?=
KU-19-19	NE\wcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7PdmZKSzVyPUCuOlQ2QDZizszN	M3LpenNCVkeHUh?=
COLO-684	NVrtTW5pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYOxb\|I2UUN3ME2wMlY2PjFzIN88US=>	NF6wS3NUSU6JRWK=
LS-1034	NF7GfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwNkW4NVkh\|ryP	Mn;4V2FPT0WU
RT-112	NHnFe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzmTWM2OD1yLk[2OVg4KM7:TR?=	NGnUXWJUSU6JRWK=
Capan-2	M{PNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrDcpc6UUN3ME2wMlY3PjJ{IN88US=>	M3PRVHNCVkeHUh?=
HSC-4	MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXWOVB{UUN3ME2wMlY3Pjl6IN88US=>	NHfUVJdUSU6JRWK=
COLO-824	NYPpcmpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlWwTWM2OD1yLk[3PFI{KM7:TR?=	NEPhfJNUSU6JRWK=
NCI-H2170	NG[4R21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\FbVU6UUN3ME2wMlY5OjV6IN88US=>	NWC2O2xEW0GQR1XS
GDM-1	M2q0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfNW3dKSzVyPUCuOlg1QTRizszN	MVHTRW5ITVJ?
KP-4	Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnVPVhKSzVyPUCuOlk2PzNizszN	MWnTRW5ITVJ?
VA-ES-BJ	NXy4fZNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHsNFZKSzVyPUCuOlk6QDZizszN	NFu1c3VUSU6JRWK=
KM-H2	NH\kVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnqO5lsUUN3ME2wMlcxODlzIN88US=>	NFvhRVZUSU6JRWK=
HH	M3X2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPp[G5KSzVyPUCuO\|A3PjJizszN	NXTtfXA3W0GQR1XS
DK-MG	NUiwNVRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHsdJJKUUN3ME2wMlcyODF4IN88US=>	NYHo[GxNW0GQR1XS
VM-CUB-1	NFnSUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnsTWM2OD1yLkexNlU6KM7:TR?=	NUfadYNsW0GQR1XS
COLO-829	M2ricmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXIeGlEUUN3ME2wMlcyQTh3IN88US=>	MkX3V2FPT0WU
OMC-1	NYnSN4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;MdZJVUUN3ME2wMlczOTB2IN88US=>	NWDmeXV7W0GQR1XS
NB12	M2nEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrL[FNKSzVyPUCuO\|I2ODRizszN	MkHQV2FPT0WU
NCI-H28	NEC2[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrSTWM2OD1yLke0NFg{KM7:TR?=	MlvGV2FPT0WU
A673	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HYRmlEPTB;MD63OVE4PyEQvF2=	M3XJeXNCVkeHUh?=
LB2241-RCC	NIDSR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M322VWlEPTB;MD63OlA5PyEQvF2=	NWDhU3dnW0GQR1XS
CCRF-CEM	M3vOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmiwTWM2OD1yLke3NFUzKM7:TR?=	M136XnNCVkeHUh?=
NCI-H510A	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPQTWM2OD1yLke3NVg3KM7:TR?=	NV7DVWtKW0GQR1XS
SW48	M2T3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV31VXJxUUN3ME2wMlc4OzN\|IN88US=>	NHG2e\|NUSU6JRWK=
NCI-H2081	NVLne2RzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF36TGxKSzVyPUCuO\|gyPDdizszN	M4PvT3NCVkeHUh?=
RMG-I	M1\5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwN{iyNVIh\|ryP	NWHhSmk4W0GQR1XS
LU-99A	NIPlbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHBTWM2OD1yLke4OFE{KM7:TR?=	NHvSOI1USU6JRWK=
KP-N-YS	NFXT[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HsPWlEPTB;MD63PFkzOSEQvF2=	NHL5V2RUSU6JRWK=
MDA-MB-231	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rrbWlEPTB;MD64NFE{OSEQvF2=	MWjTRW5ITVJ?
U031	M{TCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vQfGlEPTB;MD64NVQzOyEQvF2=	NX;ZW2MxW0GQR1XS
EVSA-T	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XPUmlEPTB;MD64NVY4OiEQvF2=	M332OXNCVkeHUh?=
MDA-MB-157	NGPVOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjXcpZKSzVyPUCuPFIzPzFizszN	M{TuN3NCVkeHUh?=
EHEB	NX;ubXgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1P3RmlEPTB;MD64NlI4PiEQvF2=	NHzLS3VUSU6JRWK=
KINGS-1	NF3BNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\mTWM2OD1yLkiyOVU2KM7:TR?=	MmO5V2FPT0WU
23132-87	M2W2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;1fVlKSzVyPUCuPFI5PDNizszN	MkXPV2FPT0WU
EFO-21	NUPGZnk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDpUm1KSzVyPUCuPFQxQDlizszN	NIHSWmNUSU6JRWK=
DOK	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nKVWlEPTB;MD64OFgh\|ryP	M1e0NHNCVkeHUh?=
NCI-H2171	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rwTmlEPTB;MD64OFk3KM7:TR?=	MnjOV2FPT0WU
NCI-SNU-5	NIHMO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XSfGlEPTB;MD64OVU4KM7:TR?=	NFjqWFNUSU6JRWK=
SK-N-DZ	MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwOEW5OFMh\|ryP	M1L5R3NCVkeHUh?=
SNU-C2B	M2[zeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwOE[4NFEh\|ryP	MVPTRW5ITVJ?
CP66-MEL	M{Ww[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwOEexNUDPxE1?	MYjTRW5ITVJ?
SN12C	Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInE[IxKSzVyPUCuPFg3OzdizszN	NEnwW5RUSU6JRWK=
A172	M3nQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwOEi2PVgh\|ryP	MkXzV2FPT0WU
NCI-H2347	NYDUb25HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwOEi3OVMh\|ryP	M13KXHNCVkeHUh?=
NCI-H2228	NEC3[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF2zb2ZKSzVyPUCuPFk{OzlizszN	MWTTRW5ITVJ?
SNU-387	NI\kPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrvUVhXUUN3ME2wMlkxOjZ2IN88US=>	NEfR[G1USU6JRWK=
SK-MEL-24	M1HqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3MbZNOUUN3ME2wMlkyOzR2IN88US=>	NVnE[YhYW0GQR1XS
MDA-MB-468	M33iR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjD[mlKSzVyPUCuPVE4OyEQvF2=	M1jnPXNCVkeHUh?=
NCI-H1694	M1fXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLteHZKSzVyPUCuPVE5PzZizszN	M1ywS3NCVkeHUh?=
CCF-STTG1	NVPvSFB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHD[GtjUUN3ME2wMlkzPjN5IN88US=>	MkezV2FPT0WU
K052	NXnsVIhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LkS2lEPTB;MD65OFA1PyEQvF2=	NHP0XHNUSU6JRWK=
NCI-H446	NFTZUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HJVmlEPTB;MD65OVAyKM7:TR?=	NX73b5llW0GQR1XS
MFE-280	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\ub\|NKSzVyPUCuPVYzQTFizszN	NXv5S\|VRW0GQR1XS
KU812	M1fwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;4V2VKSzVyPUCuPVk{QDlizszN	NWf5WYtIW0GQR1XS
MDA-MB-361	M3riUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrlcHdKSzVyPUCuPVk4PzdizszN	NInMWoZUSU6JRWK=
Raji	M3fhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HyZmlEPTB;MT6wNlI3PyEQvF2=	MX7TRW5ITVJ?
TE-6	MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PCPGlEPTB;MT6wN\|U3PiEQvF2=	M17TW3NCVkeHUh?=
CAL-148	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{K2ZmlEPTB;MT6wOFQ1OyEQvF2=	M4e0d3NCVkeHUh?=
NCI-H1963	NXLLTpFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17ydmlEPTB;MT6wOFU2OyEQvF2=	M4LRN3NCVkeHUh?=
SK-N-AS	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmP3TWM2OD1zLkC0Olg2KM7:TR?=	M1OzWHNCVkeHUh?=
RERF-LC-MS	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jLeGlEPTB;MT6wOlM1QSEQvF2=	MnTFV2FPT0WU
BEN	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUH6ToRrUUN3ME2xMlA4OTN5IN88US=>	NVTXfW9oW0GQR1XS
CAS-1	Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTFwMEmxNlMh\|ryP	MYnTRW5ITVJ?
SW780	NY\aNI9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrWdlNKSzVyPUGuNFkyQDFizszN	NXnDZnd5W0GQR1XS
LU-65	NH3ZdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXK3WXJNUUN3ME2xMlA6PDFizszN	MoTTV2FPT0WU
D-283MED	M4exOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XUNWlEPTB;MT6xNlI4OiEQvF2=	MYnTRW5ITVJ?
HCC2157	NFK0V2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTFwMUO2OFIh\|ryP	NVfBOFVXW0GQR1XS
RCC10RGB	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Hk[2lEPTB;MT6xOFAxPiEQvF2=	NX7lbnFsW0GQR1XS
PLC-PRF-5	NFvqSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\zNHMzUUN3ME2xMlE2OjJ7IN88US=>	MVLTRW5ITVJ?
H4	Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nxR2lEPTB;MT6xOVQ{QSEQvF2=	NE\uXppUSU6JRWK=
TUR	NF76VohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3kcIVDUUN3ME2xMlE2PzV{IN88US=>	NV;TenVvW0GQR1XS
NCI-H2141	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfWVplKSzVyPUGuNVg6PDZizszN	NHz0NVNUSU6JRWK=
PFSK-1	NGTrWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljjTWM2OD1zLkKwOVMzKM7:TR?=	M163ZXNCVkeHUh?=
SK-MEL-28	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTFwMkOyNlEh\|ryP	M1XIRnNCVkeHUh?=
SCC-9	MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rLXWlEPTB;MT6yN\|Y3PSEQvF2=	M2HLXXNCVkeHUh?=
T47D	NHqyXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjWPYdLUUN3ME2xMlI{Pjl4IN88US=>	Mmn6V2FPT0WU
TCCSUP	M1jKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTiTWM2OD1zLkK1NFI6KM7:TR?=	MXLTRW5ITVJ?
SU-DHL-1	NYTMWINWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\Eem5PUUN3ME2xMlI2OTF6IN88US=>	NF;ud2pUSU6JRWK=
HL-60	M4Tj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTFwMkW1PFgh\|ryP	MkTaV2FPT0WU
NCI-H1436	MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mni2TWM2OD1zLkK2NVQ6KM7:TR?=	NHu1bolUSU6JRWK=
DMS-114	NVfmRocyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTFwMk[2N\|Ih\|ryP	MWnTRW5ITVJ?
BOKU	NXXqc4lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\TZYZKSzVyPUGuNlgxQTVizszN	MV3TRW5ITVJ?
MS-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTFwMkmwOlkh\|ryP	M4LG[XNCVkeHUh?=
NCI-H661	NV25UGQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH1TWM2OD1zLkOwOFc5KM7:TR?=	NFrBVnlUSU6JRWK=
HT-3	NWH0UnNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHG0XYNKSzVyPUGuN\|A2OjlizszN	NV21cpc3W0GQR1XS
CAL-54	M4\IdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPp[5FKSzVyPUGuN\|A4OjVizszN	MYXTRW5ITVJ?
SW1463	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTFwM{G4O\|Ih\|ryP	Mm\4V2FPT0WU
COLO-668	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTIfpVyUUN3ME2xMlM{ODV4IN88US=>	NEi0eYdUSU6JRWK=
PANC-08-13	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7OTXh2UUN3ME2xMlM{QDB\|IN88US=>	M4XnUXNCVkeHUh?=
BB49-HNC	M2TEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTFwM{SwNUDPxE1?	NX7vXmZYW0GQR1XS
M059J	NUjmWYFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELTZ4pKSzVyPUGuN\|U5OzJizszN	MVvTRW5ITVJ?
NCCIT	NIfwbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoWxTWM2OD1zLkO3PVg5KM7:TR?=	NWPJXHQ5W0GQR1XS
LN-405	NEfXdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjvTWM2OD1zLkO5NlY1KM7:TR?=	Mo\FV2FPT0WU
UMC-11	NYjqeHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\5TmlEPTB;MT6zPVk6PiEQvF2=	NIrUV4xUSU6JRWK=
NB5	MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDsSHJTUUN3ME2xMlQyOjJ5IN88US=>	MYjTRW5ITVJ?
TE-441-T	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DqemlEPTB;MT60NlgyPyEQvF2=	Mmj4V2FPT0WU
ME-180	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7aeGhKSzVyPUGuOFQ{QTJizszN	MoDDV2FPT0WU
HCC70	NIfYeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTpTWM2OD1zLkS2NFk3KM7:TR?=	MlLrV2FPT0WU
no-10	NFPncZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTFwNE[xPFEh\|ryP	NGrRXmJUSU6JRWK=
JEG-3	NYnZNoFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInGUYNKSzVyPUGuOVAyOzJizszN	MX\TRW5ITVJ?
no-11	NVTKTVNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEj6W41KSzVyPUGuOVA5QDJizszN	MUDTRW5ITVJ?
CHP-126	NWjyXoVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2W5emlEPTB;MT61OlY6OSEQvF2=	NE[1flBUSU6JRWK=
EGI-1	NHPFWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjJXIdSUUN3ME2xMlU5ODJ3IN88US=>	NIn2XlBUSU6JRWK=
D-392MG	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDYTWM2OD1zLkW5OlMh\|ryP	NXvafVRmW0GQR1XS
RT4	NELjV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjPc41FUUN3ME2xMlU6PjN5IN88US=>	MWTTRW5ITVJ?
A204	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HCPGlEPTB;MT61PVgxOSEQvF2=	M{LlUnNCVkeHUh?=
NCI-H1304	NH;yfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTFwNkO1PVEh\|ryP	M37JfnNCVkeHUh?=
Becker	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jod2lEPTB;MT62OFI1OSEQvF2=	NFXS[WhUSU6JRWK=
OE19	NGPnbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULi[WtjUUN3ME2xMlY2PTF6IN88US=>	NH;wcI1USU6JRWK=
EKVX	Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHDPWZpUUN3ME2xMlY2PjF6IN88US=>	M4n1bXNCVkeHUh?=
KLE	NVPVcopoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITzU2JKSzVyPUGuOlU4OTRizszN	MUHTRW5ITVJ?
K-562	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLje5FWUUN3ME2xMlY4ODN5IN88US=>	MYHTRW5ITVJ?
MDA-MB-175-VII	Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLaeoI{UUN3ME2xMlY5QTl5IN88US=>	NHLWUGJUSU6JRWK=
NCI-H716	NWTyVmVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3S5SGlEPTB;MT62PVMxPCEQvF2=	Mor0V2FPT0WU
Caov-3	M2nQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLjTWM2OD1zLk[5OFE{KM7:TR?=	MkjVV2FPT0WU
HCC1187	NIjQenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rEbmlEPTB;MT63NFU1PSEQvF2=	NXy3cYNbW0GQR1XS
CAKI-1	M2\YWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XXVGlEPTB;MT63NlI6OiEQvF2=	NIraS21USU6JRWK=
MOLT-16	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTFwN{OzNFch\|ryP	Ml;rV2FPT0WU
PC-3	NWf0VYFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTFwN{WwPEDPxE1?	NELvN5ZUSU6JRWK=
DV-90	NUXXZox6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLETIpDUUN3ME2xMlc2PTh3IN88US=>	NFHWenpUSU6JRWK=
RXF393	M4H2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTBd3pZUUN3ME2xMlc4Ojl2IN88US=>	NVLIRVF7W0GQR1XS
SK-NEP-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPGWpJKSzVyPUGuPFI{OzlizszN	NE\ke\|lUSU6JRWK=
HCC1419	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHETWM2OD1zLkiyOlkzKM7:TR?=	NUL1VZRjW0GQR1XS
BV-173	NFPDWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXGTWM2OD1zLkiyPVk2KM7:TR?=	MULTRW5ITVJ?
MKN7	MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;ZUGFKSzVyPUGuPFkzOiEQvF2=	MoDvV2FPT0WU
LAN-6	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTFwOEm1OVMh\|ryP	M{nQSHNCVkeHUh?=
Mo-T	NVzkWpB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonLTWM2OD1zLkmwNFM6KM7:TR?=	MU\TRW5ITVJ?
HCC1395	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\ndXJKSzVyPUGuPVI5PjNizszN	NIDRTIVUSU6JRWK=
HC-1	NIjYSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\yR3R5UUN3ME2xMlk{PDdizszN	NYHXTZc6W0GQR1XS
HPAF-II	MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXkWZdKSzVyPUGuPVQ1OThizszN	NV\XbWM{W0GQR1XS
CPC-N	M4nHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnnSlV[UUN3ME2xMlk5ODB{IN88US=>	M3\INnNCVkeHUh?=
MKN45	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfkclU{UUN3ME2xMlk6OTF7IN88US=>	NV3sdpdDW0GQR1XS
NCI-H1693	M3vO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTJwMEC0N\|Mh\|ryP	MUTTRW5ITVJ?
SHP-77	NHfZUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFm4d\|lKSzVyPUKuNFA2OzNizszN	M4X2THNCVkeHUh?=
NCI-H1522	Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrMTWM2OD1{LkCxO\|I1KM7:TR?=	NH;GNodUSU6JRWK=
SW1573	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHr[FF{UUN3ME2yMlAzOiEQvF2=	MnHKV2FPT0WU
DBTRG-05MG	MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;xTWM2OD1{LkC2NFg4KM7:TR?=	MYnTRW5ITVJ?
SCC-4	NXrEbYhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3KTWM2OD1{LkG0N\|Eh\|ryP	NXzoZ2JIW0GQR1XS
DMS-153	NXXjPW1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTJwMU[2Olgh\|ryP	NEPBbpZUSU6JRWK=
MDA-MB-415	MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTJwMUe1NkDPxE1?	MnfaV2FPT0WU
NCI-H2126	MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHqTWxKSzVyPUKuNlI5QDhizszN	MWnTRW5ITVJ?
MDA-MB-453	M1;QdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPkTWM2OD1{LkKzN\|Ih\|ryP	M4LaOnNCVkeHUh?=
U-87-MG	NHHrOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnG[\|NDUUN3ME2yMlI5PTl{IN88US=>	MnjwV2FPT0WU
LNCaP-Clone-FGC	MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTJwM{CxNFIh\|ryP	M4jjSXNCVkeHUh?=
NCI-H1581	MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLSTWM2OD1{LkOyNVA2KM7:TR?=	MV;TRW5ITVJ?
BC-3	Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTJwM{[1NFkh\|ryP	M1rXN3NCVkeHUh?=
HCC38	M1K4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrhdHVNUUN3ME2yMlM5PDR5IN88US=>	NU\sXGlWW0GQR1XS
HCC2218	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTJwNEC4NFkh\|ryP	NXnhZWlMW0GQR1XS
RO82-W-1	NYTJU3Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTJwNEGyOUDPxE1?	NYDwXHo2W0GQR1XS
C2BBe1	M{noXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTJwNEG1O\|gh\|ryP	NUXDSXZ3W0GQR1XS
LAMA-84	M4TveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUewVJlkUUN3ME2yMlU4OzZ6IN88US=>	NXzEZmtzW0GQR1XS
GMS-10	NHfNVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFj6V\|RKSzVyPUKuOVc3OTFizszN	MlzVV2FPT0WU
GCT	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPkUHNKSzVyPUKuOVg3QTRizszN	NYLjRYI1W0GQR1XS
SK-CO-1	M1fFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7zOpp5UUN3ME2yMlYyPjZizszN	MXrTRW5ITVJ?
NCI-H526	NWnncphZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\tTWM2OD1{Lk[zOFUh\|ryP	NH7zN\|hUSU6JRWK=
SW1088	M{\sPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\zOIxuUUN3ME2yMlc4QDN7IN88US=>	MVjTRW5ITVJ?
HT55	NWHDT3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{mxNmlEPTB;Mj63PFY6PSEQvF2=	NGrDWJNUSU6JRWK=
NB10	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXz1eWFlUUN3ME2yMlgyPzR6IN88US=>	NFPqSZJUSU6JRWK=
UACC-893	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HnRWlEPTB;Mj64OVc1QSEQvF2=	NGPrXmdUSU6JRWK=
NCI-H1618	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rHVGlEPTB;Mj64PFE2OyEQvF2=	NH;Lc5JUSU6JRWK=
NCI-H1092	NIjidXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHuTWM2OD1\|LkC3PFEzKM7:TR?=	NH6yNZFUSU6JRWK=
SBC-1	M2rHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:wR4FkUUN3ME2zMlA5PTV\|IN88US=>	Mn3YV2FPT0WU
NCI-H1623	NHHacGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfnW45FUUN3ME2zMlA6OzRizszN	M4XtcHNCVkeHUh?=
SiHa	NXTuN4VCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrzTWM2OD1\|LkGxPVc4KM7:TR?=	NGXjWHdUSU6JRWK=
D-263MG	NV;6NpkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlq4TWM2OD1\|LkG0O\|g5KM7:TR?=	M4DDXXNCVkeHUh?=
NCI-H1573	Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTNwMUm2OFEh\|ryP	NF2yO5dUSU6JRWK=
NCI-H82	MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjhTIc2UUN3ME2zMlM1PDN7IN88US=>	NUXzPFFZW0GQR1XS
NCI-H2196	NUj4OFRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;hTZZKSzVyPUOuN\|UxODhizszN	MXrTRW5ITVJ?
MFM-223	M4ribmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTNwM{ezOVEh\|ryP	MWDTRW5ITVJ?
COLO-678	M1fPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4S1UGlEPTB;Mz6zPFE5PiEQvF2=	MonHV2FPT0WU
EW-3	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTNwNEC5OUDPxE1?	MV\TRW5ITVJ?
MHH-NB-11	MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDjbo1KSzVyPUOuOFQxPjlizszN	NVKweZJwW0GQR1XS
EM-2	NHnremVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTNwNkO5PEDPxE1?	NIe2OlBUSU6JRWK=
FTC-133	M{LiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\rTWM2OD1\|Lk[1OFU5KM7:TR?=	NHj1WWxUSU6JRWK=
NCI-H209	MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13qSGlEPTB;Mz62O\|Y2OyEQvF2=	M{jkSXNCVkeHUh?=
TGBC24TKB	MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4f0PWlEPTB;Mz62PFM2PSEQvF2=	MX;TRW5ITVJ?
LC-1F	NYHBcJpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XKemlEPTB;Mz63NVc3PCEQvF2=	MorEV2FPT0WU
C-4-II	M{L3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDFdJNKSzVyPUOuO\|U3PDNizszN	NGrMcIxUSU6JRWK=
NCI-H1650	M{S4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPjd\|h[UUN3ME2zMlc5PDV3IN88US=>	M3PKcHNCVkeHUh?=
JVM-2	M1LLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTHTWM2OD1\|LkmzOlM6KM7:TR?=	MUjTRW5ITVJ?
CaR-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7xbnBKSzVyPUOuPVc3OTdizszN	M123b3NCVkeHUh?=
MDA-MB-134-VI	NWTYdIJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzGTWM2OD12LkCyPVUzKM7:TR?=	NXjmSXdUW0GQR1XS
NCI-H719	NUeyXpI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TSSGlEPTB;ND6xOVM5QCEQvF2=	NXTrcXFuW0GQR1XS
GOTO	M4DnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zJUWlEPTB;ND6yPVcxPSEQvF2=	NHLTVlJUSU6JRWK=
NCI-N87	MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\KcWRKSzVyPUSuN\|g5OjFizszN	MnriV2FPT0WU
NB6	NHrFVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTRwNEK1NFkh\|ryP	MVjTRW5ITVJ?
DSH1	MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\5O3JKSzVyPUSuOFcyOTZizszN	NH;4XZFUSU6JRWK=
BT-20	NFnu[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTRwNEmwNFIh\|ryP	MnjiV2FPT0WU
NCI-H1882	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXW1[npCUUN3ME20MlUxPTdizszN	NYjTVo5GW0GQR1XS
WM-115	NHj6PYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTiTWM2OD12LkWwPFgyKM7:TR?=	Mn;oV2FPT0WU
SKG-IIIa	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jmWmlEPTB;ND62O\|c4KM7:TR?=	NHTUbmhUSU6JRWK=
NCI-H69	NVnGVoNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTZV4NmUUN3ME20MlcxOjd3IN88US=>	NH;oZ21USU6JRWK=
MSTO-211H	NIHBd2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGr0PZhKSzVyPUSuPFM2PjVizszN	M2riOHNCVkeHUh?=
Mewo	NV7pRYNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4G1cWlEPTB;ND65OlMyOyEQvF2=	NYXq[WlEW0GQR1XS
GI-ME-N	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTVwMEC1NFkh\|ryP	MX;TRW5ITVJ?
T98G	NUDLcVJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TQfGlEPTB;NT6wOlUxQCEQvF2=	MVzTRW5ITVJ?
ECC4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HMdGlEPTB;NT6wPVM4OiEQvF2=	NWi0SJlJW0GQR1XS
EW-11	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PmWWlEPTB;NT6xPFA6QSEQvF2=	MX;TRW5ITVJ?
COLO-800	NEHaW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTVwMUmzOFkh\|ryP	NVnYS3doW0GQR1XS
NCI-H1755	NUC1dZNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DtSmlEPTB;NT6yN\|AzPyEQvF2=	MVLTRW5ITVJ?
KMS-12-PE	NH\XbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHX4bYFKSzVyPUWuN\|UxQDVizszN	M1LjdXNCVkeHUh?=
HCC1954	MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfyc2ZKSzVyPUWuPFU6PzFizszN	NHT6VlVUSU6JRWK=
NCI-H187	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTVwOUK5PFkh\|ryP	MVnTRW5ITVJ?
LU-165	NInrblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTVwOUmwNFIh\|ryP	NW\qWG5VW0GQR1XS
YAPC	NIrWfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYGxNolMUUN3ME21Mlk6ODZ6IN88US=>	M2XieXNCVkeHUh?=
LU-139	NIfZT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTZwMEizOlgh\|ryP	M3rnOHNCVkeHUh?=
D-502MG	NWnYU2I1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTZwM{KwOFch\|ryP	MkX3V2FPT0WU
IST-SL1	MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPoTWM2OD14LkWzPVQ5KM7:TR?=	NXXSPGdUW0GQR1XS
DG-75	NXPqeJdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTZwOEi3PFYh\|ryP	NHHhSWhUSU6JRWK=
NCI-H1155	M1G0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nuSmlEPTB;Nj65OVU5OSEQvF2=	M1K0PXNCVkeHUh?=
EFE-184	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrNUZhKSzVyPUeuN\|E3QTVizszN	NVfQZ2NEW0GQR1XS
AsPC-1	M4\ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPwTWM2OD15LkS4PFA4KM7:TR?=	M2DWWnNCVkeHUh?=
SW948	NV3VcY9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTDU5lrUUN3ME23MlU5Ozl3IN88US=>	MUDTRW5ITVJ?
NCI-H524	Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmKxTWM2OD17LkW4OlI5KM7:TR?=	NVrjUZhVW0GQR1XS
KOSC-2	MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTPTWM2OD17Lk[yPFM1KM7:TR?=	MU\TRW5ITVJ?
T-24	M2LwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTlwOUS0NVUh\|ryP	MVrTRW5ITVJ?
NCI-H748	MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1q4[WlEPTB;MUCuOlM6PyEQvF2=	NYS5bFJYW0GQR1XS
NCI-H23	NF7rVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPPRWxKSzVyPUGwMlY1PDJizszN	NX7G[5YxW0GQR1XS
UACC-812	NX;mUHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorSTWM2OD1zMT63NVch\|ryP	M4q3V3NCVkeHUh?=
SCLC-21H	NVLMfm9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTF{LkG1OVEh\|ryP	NHGxSHpUSU6JRWK=
NCI-SNU-16	NInpWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvKTYZDUUN3ME2xN{4yOjV6IN88US=>	NXrzWI5kW0GQR1XS
HD-MY-Z	M{LNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTF2Lk[zOlMh\|ryP	M4PhdXNCVkeHUh?=
SK-N-FI	NV\PdpJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTF2Lki5NVIh\|ryP	MUjTRW5ITVJ?
LB647-SCLC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\3boFKSzVyPUG1MlcyQTVizszN	NFTQcJFUSU6JRWK=
NCI-H345	NYLKcGdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTF5LkO0N{DPxE1?	NF;YPYRUSU6JRWK=
NCI-H1563	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1uxRmlEPTB;MUiuO\|YxOSEQvF2=	NI\FSFRUSU6JRWK=
RL	NVvWc5U2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jpWWlEPTB;MkGuNlY2PiEQvF2=	M3XEWHNCVkeHUh?=
KY821	NVHKXnU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;VNmlEPTB;MkKuNFU2OyEQvF2=	NXPKd3ZWW0GQR1XS
JVM-3	NXvHbmdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7GcHFKSzVyPUK1MlA1OTNizszN	NXPZdJk{W0GQR1XS
NCI-H1793	M3K3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{C1NmlEPTB;MkiuOVQ6QSEQvF2=	MlLWV2FPT0WU
LU-134-A	NH\iVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDUfJVCUUN3ME2zNE4zODN5IN88US=>	M3S5VXNCVkeHUh?=
NCI-H1395	NH;jblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnrdXlKSzVyPUOyMlI1OzFizszN	MUjTRW5ITVJ?
NCI-H1993	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPzTWM2OD1\|Mj64NlE5KM7:TR?=	Mlu3V2FPT0WU
P31-FUJ	NFPMbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjmZYFKSzVyPUOzMlQ5QTlizszN	MlnLV2FPT0WU
LS-513	M{jONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHGyVnJKSzVyPUO1Mlg5PzlizszN	NFn0cIZUSU6JRWK=
SK-MEL-1	M{XFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XBV2lEPTB;NECuN\|Q6QSEQvF2=	NVTTWWRqW0GQR1XS
SW684	NX3K[Yh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mny3TWM2OD12Mz65OlYyKM7:TR?=	NFjWcZpUSU6JRWK=
COR-L88	Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPaU4FsUUN3ME20OE4xPjZ3IN88US=>	MUfTRW5ITVJ?
NCI-H889	NHvYOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTR3LkCwPFch\|ryP	NWDXXmkxW0GQR1XS
TALL-1	NVzZOVQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTR4LkGxPVkh\|ryP	NHXySWFUSU6JRWK=
KARPAS-299	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPLN5BKSzVyPUS3MlE6QTNizszN	NEnVSXZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	+ Expand Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	+ Expand Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

+ Expand

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01563601	Withdrawn	Extensive-stage Small Cell Lung Cancer	Cephalon\|Teva Pharmaceutical Industries	August 2012	Phase 3
NCT01563601	Withdrawn	Extensive-stage Small Cell Lung Cancer	Cephalon\|Teva Pharmaceutical Industries	August 2012	Phase 3
NCT01238146	Withdrawn	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	National Cancer Institute (NCI)	October 2010	Phase 1\|Phase 2
NCT01238146	Withdrawn	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	National Cancer Institute (NCI)	October 2010	Phase 1\|Phase 2
NCT00918931	Terminated	Leukemia\|Systemic Mastocytosis	M.D. Anderson Cancer Center\|Gemin X	June 2009	Phase 2
NCT00933985	Terminated	Acute Leukemias of Ambiguous Lineage\|Acute Undifferentiated Leukemia\|Angioimmunoblastic T-cell Lymphoma\|Blastic Phase Chronic Myelogenous Leukemia\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK/T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent/Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Small Intestine Lymphoma\|Unspecified Childhood Solid Tumor Protocol Specific	National Cancer Institute (NCI)	June 2009	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 28 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 28 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)